In contrast, Akuta et al. [43] reported histological improvement in the scores of fibrosis stage by 33% after treatment with canagliflozin for 24 weeks in patients with T2DM and NAFLD. Also, Arai et al. showed sustained improvement in the FIB-4 index after 3 years of follow-up by adding SGLT2 inhibitors [44]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.